Resistance to angiogenesis inhibitors in renal cell carcinoma
- PMID: 22173604
Resistance to angiogenesis inhibitors in renal cell carcinoma
Abstract
Antiangiogenic drugs are now available for treatment of renal cell carcinoma and are utilized sequentially to prolong clinical benefit in patients with recurrent disease. These antiangiogenic agents are disease stabilizing in most cases, and resistance eventually develops over time. Because different combinations and sequences are tested in clinical trials, resistance patterns and mechanisms should be investigated. Much effort has been devoted to understanding the biology and elucidating the pathways and additional targets during tumorigenesis and metastasis. Resistance appears to be either primary nonresponsiveness, or it is acquired over time and related to various evasive/escape mechanisms that the tumor develops in response to therapy. Primary resistance is less common, but may be due to an intrinsic redundancy of available angiogenic signals for the tumor, causing unresponsiveness to vascular endothelial growth factor (VEGF)-targeted therapies. During acquired resistance, tumors may activate an "angiogenic switch," which leads to either upregulation of the existing VEGF pathway or recruitment of alternative factors responsible for tumor revascularization. Rationally designed preclinical and clinical trials will shed additional light on our understanding of the potential mechanisms of resistance to antiangiogenic drugs.
Similar articles
-
Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.Clin Genitourin Cancer. 2012 Jun;10(2):77-83. doi: 10.1016/j.clgc.2012.01.010. Epub 2012 Feb 28. Clin Genitourin Cancer. 2012. PMID: 22382009 Review.
-
Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.Biochim Biophys Acta. 2014 Jan;1845(1):31-41. doi: 10.1016/j.bbcan.2013.10.001. Epub 2013 Oct 14. Biochim Biophys Acta. 2014. PMID: 24135488 Review.
-
Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.Hematol Oncol Clin North Am. 2004 Oct;18(5):1143-59, ix-x. doi: 10.1016/j.hoc.2004.06.003. Hematol Oncol Clin North Am. 2004. PMID: 15474339 Review.
-
Résistance aux inhibiteurs des tyrosines kinases dans le cancer du rein.Bull Cancer. 2018 Dec;105 Suppl 3:S255-S260. doi: 10.1016/S0007-4551(18)30380-1. Bull Cancer. 2018. PMID: 30595154 Review. French.
-
Novel antiangiogenic therapies for renal cell cancer.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6377S-81S. doi: 10.1158/1078-0432.CCR-050007. Clin Cancer Res. 2004. PMID: 15448034 Review.
Cited by
-
Curcumin Inhibits Vasculogenic Mimicry via Regulating ETS-1 in Renal Cell Carcinoma.Curr Cancer Drug Targets. 2024;24(10):1031-1046. doi: 10.2174/0115680096277126240102060617. Curr Cancer Drug Targets. 2024. PMID: 38299401
-
Integration of NRP1, RGS5, and FOXM1 expression, and tumour necrosis, as a postoperative prognostic classifier based on molecular subtypes of clear cell renal cell carcinoma.J Pathol Clin Res. 2021 Nov;7(6):590-603. doi: 10.1002/cjp2.232. Epub 2021 Jul 2. J Pathol Clin Res. 2021. PMID: 34212534 Free PMC article.
-
Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.J Clin Invest. 2019 Feb 1;129(2):442-451. doi: 10.1172/JCI120855. Epub 2019 Jan 7. J Clin Invest. 2019. PMID: 30614813 Free PMC article. Review.
-
Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.PLoS One. 2018 Feb 6;13(2):e0192464. doi: 10.1371/journal.pone.0192464. eCollection 2018. PLoS One. 2018. PMID: 29408858 Free PMC article.
-
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.Oncotarget. 2016 Jun 21;7(25):38467-86. doi: 10.18632/oncotarget.9542. Oncotarget. 2016. PMID: 27509260 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical